Skip to main content
. 2020 Jan 10;29(12):1933–1949. doi: 10.1093/hmg/ddz317

Figure 5.

Figure 5

Reduction of microglia activation and astrogliosis in treated K14-lnl/lnl mice. (A) Brain sections stained for the microglial marker CD68 and (C) quantification of immunoreactivity in cortex (S1BF), hippocampus (CA1/CA2), thalamus (VPM/VPL), cerebellum (10Cb) and brain stem (Gi). Gene therapy normalized microglia activation to wild-type levels in P66-treated K14-lnl/lnl mice. Scale bars: low magnification 100 μm; high magnification 60 μm. (B) Immunochemical staining of brain sections for the astrocyte marker GFAP and (D) quantification of immune reactivity in cortex (S1BF), hippocampus (CA1/CA2), thalamus (VPM/VPL), cerebellum (10Cb) and brain stem (Gi). Gene therapy partially reduced neuroinflammation in cortex, thalamus and brain stem of K14-lnl/lnl treated brains. Scale bars: low magnification 100 μm; high magnification 60 μm.